Bevacizumab (Avastin) is a widely used recombinant monoclonal antibody that inhibits VEGF and was studied in several clinical trials in patients with HHT (39, 63, 64). The gene discussed is VEGFA; the disease is hereditary hemorrhagic telangiectasia.